{
    "info": {
        "nct_id": "NCT05329103",
        "official_title": "An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors",
        "inclusion_criteria": "Inclusion criteria:\n\n* ECOG of 0 or 1\n* Have a diagnosis of advanced or metastatic solid tumor that has progressed after prior standard therapy, have been intolerant or ineligible for standard therapy, or have a malignancy for which there is no approved therapy considered standard of care\n* Have at least 1 documented measurable lesion as detected by radiological methods at study entry as per Response Evaluation Criteria in Solid Tumors v1.1\n* Have adequate bone marrow reserve\n* Have adequate liver function\n* Have adequate renal function\n* Have completed prior anticancer therapy, including investigational agents, ≥28 days or 5 half lives, whichever is shorter, prior to study treatment\n* Have resolution of any clinically significant toxic effects of prior therapy\n\nExclusion criteria:\n\n* Have primary central nervous system tumors\n* Have brain or spinal metastases, except if treated by surgery, surgery plus focal radiotherapy, or radiotherapy alone, with no evidence of progression or hemorrhage ≤14 days prior to the first dose of PEEL-224. Have craniospinal radiotherapy ≤12 weeks prior to the first dose of PEEL-224\n* Have significant abnormalities in the level of serum electrolytes\n* Have received neutrophil growth factor support ≤14 days prior to the first dose of PEEL 224\n* Have an active infection ≤14 days prior to the first dose of PEEL-224\n* Use of strong cytochrome P450 (CYP)1A2 and CYP3A4 inhibitors and/or inducers ≤14 days prior to the first dose of PEEL-224 or during the study\n* Use of systemic corticosteroids ≤14 days prior to the first dose of PEEL-224\n* Are known to be HIV-positive, unless CD4 + lymphocyte count ≥ 300/μL, undetectable viral load; AND Receiving anti-retroviral therapy.\n* Have uncontrolled hepatitis B infection or hepatitis C infection;\n* Are pregnant or lactating, plan to become pregnant, or plan to donate gametes (ova or sperm) for in vitro fertilization during the study period or for 90 days after the patient's last study-related visit (for eligible patients only, if applicable). Eligible female patients unwilling to employ appropriate contraceptive measures to ensure that pregnancy does not occur during the study will be excluded;\n* Have evidence of another malignancy ≤2 years prior to screening (except in situ non melanoma skin cell cancers and in situ cervical carcinoma);\n* Are currently enrolled in another therapeutic clinical study or a non-therapeutic clinical study that will conflict with scheduled visits required by this study;\n* Have clinically significant, uncontrolled cardiovascular disease\n* Have history of cerebrovascular accident, transient ischemic attack, or thrombosis requiring treatment ≤3 months prior to the first dose of PEEL-224\n* Have received or will receive a live vaccine ≤14 days prior to the first dose of PEEL 224.\n* Have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection ≤14 days of the Screening Visit.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Have adequate bone marrow reserve",
            "criterions": [
                {
                    "exact_snippets": "adequate bone marrow reserve",
                    "criterion": "bone marrow reserve",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have uncontrolled hepatitis B infection or hepatitis C infection;",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled hepatitis B infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled ... hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have significant abnormalities in the level of serum electrolytes",
            "criterions": [
                {
                    "exact_snippets": "significant abnormalities in the level of serum electrolytes",
                    "criterion": "serum electrolytes",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "significant abnormalities"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have resolution of any clinically significant toxic effects of prior therapy",
            "criterions": [
                {
                    "exact_snippets": "resolution of any clinically significant toxic effects of prior therapy",
                    "criterion": "toxic effects of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have clinically significant, uncontrolled cardiovascular disease",
            "criterions": [
                {
                    "exact_snippets": "clinically significant, uncontrolled cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of systemic corticosteroids ≤14 days prior to the first dose of PEEL-224",
            "criterions": [
                {
                    "exact_snippets": "Use of systemic corticosteroids ≤14 days prior to the first dose of PEEL-224",
                    "criterion": "systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to the first dose of PEEL-224"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have adequate liver function",
            "criterions": [
                {
                    "exact_snippets": "adequate liver function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have primary central nervous system tumors",
            "criterions": [
                {
                    "exact_snippets": "Have primary central nervous system tumors",
                    "criterion": "primary central nervous system tumors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have evidence of another malignancy ≤2 years prior to screening (except in situ non melanoma skin cell cancers and in situ cervical carcinoma);",
            "criterions": [
                {
                    "exact_snippets": "evidence of another malignancy ≤2 years prior to screening",
                    "criterion": "history of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received or will receive a live vaccine ≤14 days prior to the first dose of PEEL 224.",
            "criterions": [
                {
                    "exact_snippets": "Have received or will receive a live vaccine ≤14 days prior to the first dose of PEEL 224.",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time before first dose of PEEL 224",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection ≤14 days of the Screening Visit.",
            "criterions": [
                {
                    "exact_snippets": "Have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection",
                    "criterion": "SARS-CoV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "≤14 days of the Screening Visit",
                    "criterion": "time since positive SARS-CoV-2 test",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have adequate renal function",
            "criterions": [
                {
                    "exact_snippets": "adequate renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of strong cytochrome P450 (CYP)1A2 and CYP3A4 inhibitors and/or inducers ≤14 days prior to the first dose of PEEL-224 or during the study",
            "criterions": [
                {
                    "exact_snippets": "Use of strong cytochrome P450 (CYP)1A2 and CYP3A4 inhibitors and/or inducers ≤14 days prior to the first dose of PEEL-224 or during the study",
                    "criterion": "use of strong CYP1A2 and CYP3A4 inhibitors and/or inducers",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have brain or spinal metastases, except if treated by surgery, surgery plus focal radiotherapy, or radiotherapy alone, with no evidence of progression or hemorrhage ≤14 days prior to the first dose of PEEL-224. Have craniospinal radiotherapy ≤12 weeks prior to the first dose of PEEL-224",
            "criterions": [
                {
                    "exact_snippets": "Have brain or spinal metastases",
                    "criterion": "brain or spinal metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except if treated by surgery, surgery plus focal radiotherapy, or radiotherapy alone",
                    "criterion": "treatment of brain or spinal metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "surgery",
                                "surgery plus focal radiotherapy",
                                "radiotherapy alone"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "no evidence of progression or hemorrhage ≤14 days prior to the first dose of PEEL-224",
                    "criterion": "progression or hemorrhage of brain or spinal metastases",
                    "requirements": [
                        {
                            "requirement_type": "evidence of progression",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "evidence of hemorrhage",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time since last progression or hemorrhage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Have craniospinal radiotherapy ≤12 weeks prior to the first dose of PEEL-224",
                    "criterion": "craniospinal radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since craniospinal radiotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have completed prior anticancer therapy, including investigational agents, ≥28 days or 5 half lives, whichever is shorter, prior to study treatment",
            "criterions": [
                {
                    "exact_snippets": "Have completed prior anticancer therapy, including investigational agents, ≥28 days or 5 half lives, whichever is shorter, prior to study treatment",
                    "criterion": "prior anticancer therapy (including investigational agents)",
                    "requirements": [
                        {
                            "requirement_type": "completion before study treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interval since completion",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are pregnant or lactating, plan to become pregnant, or plan to donate gametes (ova or sperm) for in vitro fertilization during the study period or for 90 days after the patient's last study-related visit (for eligible patients only, if applicable). Eligible female patients unwilling to employ appropriate contraceptive measures to ensure that pregnancy does not occur during the study will be excluded;",
            "criterions": [
                {
                    "exact_snippets": "Are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "plan to become pregnant ... during the study period or for 90 days after the patient's last study-related visit",
                    "criterion": "pregnancy intention",
                    "requirements": [
                        {
                            "requirement_type": "intention to become pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "plan to donate gametes (ova or sperm) for in vitro fertilization during the study period or for 90 days after the patient's last study-related visit",
                    "criterion": "intention to donate gametes for IVF",
                    "requirements": [
                        {
                            "requirement_type": "intention to donate gametes",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Eligible female patients unwilling to employ appropriate contraceptive measures to ensure that pregnancy does not occur during the study",
                    "criterion": "contraceptive use in eligible female patients",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have at least 1 documented measurable lesion as detected by radiological methods at study entry as per Response Evaluation Criteria in Solid Tumors v1.1",
            "criterions": [
                {
                    "exact_snippets": "at least 1 documented measurable lesion as detected by radiological methods at study entry as per Response Evaluation Criteria in Solid Tumors v1.1",
                    "criterion": "measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "radiological methods"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at study entry"
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "Response Evaluation Criteria in Solid Tumors v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an active infection ≤14 days prior to the first dose of PEEL-224",
            "criterions": [
                {
                    "exact_snippets": "active infection ≤14 days prior to the first dose of PEEL-224",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to the first dose of PEEL-224"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are known to be HIV-positive, unless CD4 + lymphocyte count ≥ 300/μL, undetectable viral load; AND Receiving anti-retroviral therapy.",
            "criterions": [
                {
                    "exact_snippets": "Are known to be HIV-positive",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CD4 + lymphocyte count ≥ 300/μL",
                    "criterion": "CD4+ lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 300,
                                "unit": "μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Receiving anti-retroviral therapy",
                    "criterion": "anti-retroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a diagnosis of advanced or metastatic solid tumor that has progressed after prior standard therapy, have been intolerant or ineligible for standard therapy, or have a malignancy for which there is no approved therapy considered standard of care",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of advanced or metastatic solid tumor",
                    "criterion": "solid tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has progressed after prior standard therapy",
                    "criterion": "disease progression after standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression_status",
                            "expected_value": "progressed"
                        }
                    ]
                },
                {
                    "exact_snippets": "have been intolerant ... for standard therapy",
                    "criterion": "tolerance to standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ineligible for standard therapy",
                    "criterion": "eligibility for standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "malignancy for which there is no approved therapy considered standard of care",
                    "criterion": "availability of standard of care therapy",
                    "requirements": [
                        {
                            "requirement_type": "approved_standard_therapy_available",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have received neutrophil growth factor support ≤14 days prior to the first dose of PEEL 224",
            "criterions": [
                {
                    "exact_snippets": "Have received neutrophil growth factor support ≤14 days prior to the first dose of PEEL 224",
                    "criterion": "neutrophil growth factor support",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Inclusion criteria:",
            "criterions": []
        },
        {
            "line": "* Are currently enrolled in another therapeutic clinical study or a non-therapeutic clinical study that will conflict with scheduled visits required by this study;",
            "criterions": [
                {
                    "exact_snippets": "Are currently enrolled in another therapeutic clinical study",
                    "criterion": "enrollment in another therapeutic clinical study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "are currently enrolled in ... a non-therapeutic clinical study that will conflict with scheduled visits required by this study",
                    "criterion": "enrollment in a non-therapeutic clinical study that will conflict with scheduled visits required by this study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "conflict with scheduled visits required by this study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion criteria:",
            "criterions": []
        },
        {
            "line": "* Have history of cerebrovascular accident, transient ischemic attack, or thrombosis requiring treatment ≤3 months prior to the first dose of PEEL-224",
            "criterions": [
                {
                    "exact_snippets": "history of cerebrovascular accident ... ≤3 months prior to the first dose of PEEL-224",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of transient ischemic attack ... ≤3 months prior to the first dose of PEEL-224",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... thrombosis requiring treatment ≤3 months prior to the first dose of PEEL-224",
                    "criterion": "thrombosis requiring treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}